Anti cd3 percp

Manufactured by R&D Systems

Sourced in United States

Anti-CD3 PerCP is a laboratory reagent used for the detection and characterization of cells expressing the CD3 antigen. PerCP (Peridinin-Chlorophyll Protein Complex) is the fluorescent label conjugated to the anti-CD3 antibody, which allows for the identification of CD3-positive cells in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd56 pe, by Thermo Fisher Scientific (2 mentions) Anti cd112 pe, by R&D Systems (2 mentions) Anti cd19 fitc, by R&D Systems (2 mentions) Anti cd155 pe, by Bio-Rad (2 mentions) Anti cd5 apc and anti cd20 pe, by Merck Group (2 mentions) Anti jam 1 pe, by Merck Group (2 mentions) Fitc labelled mouse anti human igg antibody, by BD (2 mentions) Anti mica b pe, by R&D Systems (2 mentions) Anti cd69 fitc, by BD (1 mentions)

Spelling variants of this product

Anti-CD3 (40 citations)

2 protocols using anti cd3 percp

Immunophenotyping of NK and CLL Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

NK cells were identified as CD3⁻CD56⁺ and CLL cells as CD19⁺CD5⁺. Expression of CD69 on NK cells, and JAM-1, HLA-Class I, ULBP-1, ULBP-2, MICA/B, CD112, CD155 and CD20 on CLL cells, was determined by flow cytometry. Antibodies were purchased from BD Biosciences (anti-CD69 FITC (fluorescein isothiocyanate), anti-HLA-Class I PE, anti-MICA/B PE, anti-CD112 PE, anti-CD3 PerCP and anti-CD19 FITC), R&D Systems (Minneapolis, MN, USA; anti-ULBP-1 and -2 PE and anti-CD155 PE), AbD Serotec (Kidlington, UK; anti-CD56 PE), Life Technologies (anti-CD5 APC and anti-CD20 PE) and Millipore (Billerica, MA, USA; anti-JAM-1 PE). To examine the surface binding of rituximab, CLL cells were labelled for 30 min (10⁶ cells per ml) with different concentrations of rituximab (at 37 °C), washed in FACS buffer and counterstained with FITC-labelled mouse anti-human IgG antibody (BD Biosciences).

Parrish C., Scott G.B., Migneco G., Scott K.J., Steele L.P., Ilett E., West E.J., Hall K., Selby P.J., Buchanan D., Varghese A., Cragg M.S., Coffey M., Hillmen P., Melcher A.A, & Errington-Mais F. (2015). Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, 29(9), 1799-1810.

+ Open protocol

+ Expand

Characterization of NK and CLL Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

NK cells were identified as CD3⁻CD56⁺ and CLL cells as CD19⁺CD5⁺. Expression of CD69 on NK cells, and JAM-1, HLA-Class I, ULBP-1, ULBP-2, MICA/B, CD112, CD155 and CD20 on CLL cells, was determined by flow cytometry. Antibodies were purchased from BD Biosciences (anti-CD69 FITC, Anti-HLA-Class I PE, anti-MICA/B PE, anti-CD112 PE, anti-CD3 Per CP and anti-CD19 FITC), R&D Systems (Minneapolis, MN, USA; anti-ULBP-1 and -2 PE and anti-CD155 PE), AbD Serotec (Kidlington, UK;anti-CD56 PE), Life Technologies (anti-CD5 APC and anti-CD20 PE) and Millipore (Billerica, MA, USA; anti-JAM-1 PE). To examine the surface binding of rituximab, CLL cells were labelled for 30 minutes (10⁶ cells/ml) with different concentrations of rituximab (at 37°C), washed in FACS buffer, and counter stained with FITC-labelled mouse anti-human IgG antibody (BD Biosciences).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!